Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Dai Nakamatsu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1007/s10350-004-0688-7
10.1007/s10350-004-0688-7
10.1016/j.amjsurg.2004.06.046
10.1016/j.amjsurg.2004.06.046
10.1055/a-1140-3017
10.1055/a-1140-3017
10.1016/j.cgh.2021.03.046
10.1016/j.cgh.2021.03.046
10.1007/s00464-012-2439-5
10.1007/s00464-012-2439-5
10.1007/s10620-013-2876-6
10.1007/s10620-013-2876-6
10.1016/j.gie.2017.12.017
10.1016/j.gie.2017.12.017
10.1007/s00464-020-07965-y
10.1007/s00464-020-07965-y
10.3390/cancers17010087
10.3390/cancers17010087
10.1007/s00464-023-09943-6
10.1007/s00464-023-09943-6
10.1016/j.gie.2011.05.025
10.1016/j.gie.2011.05.025
10.1159/000351208
10.1159/000351208
10.1056/nejmoa1011923
10.1056/nejmoa1011923
10.1056/nejmoa1304369
10.1056/nejmoa1304369
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
2022
10.1002/jhbp.1219
10.1002/jhbp.1219
10.3390/jcm12155134
10.3390/jcm12155134
10.1007/s10350-008-9207-6
10.1007/s10350-008-9207-6
10.1055/s-0043-102403
10.1055/s-0043-102403
10.1016/s1470-2045(23)00515-6
10.1016/s1470-2045(23)00515-6
10.1200/jco.23.01601
10.1200/jco.23.01601
No additional external references are available.